Dassi N, da Cunha F, Cappellano A, de Araujo C, de Aquino D, de Almeida D
Childs Nerv Syst. 2024; 40(12):4259-4264.
PMID: 39110187
DOI: 10.1007/s00381-024-06564-9.
Lee J, Jang J, Noh J, Yang K, Pyo H
Cancers (Basel). 2024; 16(11).
PMID: 38893246
PMC: 11171223.
DOI: 10.3390/cancers16112127.
Balan L, Cimpean A, Nandarge P, Sorop B, Balan C, Balica M
Biomedicines. 2024; 12(5).
PMID: 38791070
PMC: 11117617.
DOI: 10.3390/biomedicines12051109.
Huang Z, Wu Z, Zhang L, Yan L, Jiang H, Ai J
Front Oncol. 2024; 14:1298122.
PMID: 38318115
PMC: 10838967.
DOI: 10.3389/fonc.2024.1298122.
Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L
World J Surg Oncol. 2023; 21(1):120.
PMID: 37004052
PMC: 10064711.
DOI: 10.1186/s12957-023-02961-7.
Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer.
Yang X, Weng D, Pan Q, Xiang T, Yang C, Wu Z
Front Immunol. 2022; 13:974487.
PMID: 36439119
PMC: 9686374.
DOI: 10.3389/fimmu.2022.974487.
Expert consensus on perioperative treatment for non-small cell lung cancer.
Duan J, Tan F, Bi N, Chen C, Chen K, Cheng Y
Transl Lung Cancer Res. 2022; 11(7):1247-1267.
PMID: 35958323
PMC: 9359944.
DOI: 10.21037/tlcr-22-527.
Microwave ablation vs. cryoablation for treatment of primary and metastatic pulmonary malignant tumors.
Li H, Long Y, Yan G, Bhetuwal A, Zhuo L, Yao H
Mol Clin Oncol. 2022; 16(3):62.
PMID: 35154702
PMC: 8822887.
DOI: 10.3892/mco.2022.2495.
Radiotherapy for Primary Tracheal Carcinoma: Experience at a Single Institution.
Zeng R, Wang H, Cai X, Guo X, Ping Y, Yang Q
Technol Cancer Res Treat. 2021; 20:15330338211034273.
PMID: 34372715
PMC: 8361538.
DOI: 10.1177/15330338211034273.
Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.
Zou X, Fan W, Xue M, Li J
Cancer Manag Res. 2021; 13:4013-4029.
PMID: 34040442
PMC: 8142557.
DOI: 10.2147/CMAR.S304591.
Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma.
Cai Z, He C, Zhao C, Lin X
Front Oncol. 2021; 11:611118.
PMID: 33868997
PMC: 8047640.
DOI: 10.3389/fonc.2021.611118.
CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer.
Lin Y, Li Z, Liu M, Ye H, He J, Chen J
Arch Gynecol Obstet. 2021; 304(2):495-501.
PMID: 33392721
PMC: 8277608.
DOI: 10.1007/s00404-020-05921-8.
Three Cases of Anaplastic Thyroid Carcinoma Transformation and Leukocytosis during Lenvatinib Treatment.
Iwasaki H, Toda S, Murayama D, Takahashi H
Case Rep Endocrinol. 2020; 2020:6667237.
PMID: 33224537
PMC: 7669359.
DOI: 10.1155/2020/6667237.
Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.
Grisic A, Khandelwal A, Bertolino M, Huisinga W, Girard P, Kloft C
CPT Pharmacometrics Syst Pharmacol. 2020; 9(11):628-638.
PMID: 33015996
PMC: 7679074.
DOI: 10.1002/psp4.12558.
Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Hoa N, Huy H
Cureus. 2020; 12(5):e8105.
PMID: 32426197
PMC: 7228796.
DOI: 10.7759/cureus.8105.
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.
Zang H, Peng J, Zheng H, Fan S
Front Oncol. 2020; 10:515.
PMID: 32411591
PMC: 7201048.
DOI: 10.3389/fonc.2020.00515.
Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer.
Pan Q, Gu J, Zhao J, Tang Y, Wang Q, Zhu Q
Clin Transl Immunology. 2020; 9(2):e1113.
PMID: 32076550
PMC: 7029432.
DOI: 10.1002/cti2.1113.
First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China.
Qi F, Hu X, Liu Y, Wang Z, Duan J, Wang J
Chin J Cancer Res. 2019; 31(5):749-758.
PMID: 31814679
PMC: 6856705.
DOI: 10.21147/j.issn.1000-9604.2019.05.05.
Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.
Gu N, Wang X, Di Z, Xiong J, Ma Y, Yan Y
Aging (Albany NY). 2019; 11(22):10266-10283.
PMID: 31770107
PMC: 6914387.
DOI: 10.18632/aging.102455.
Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.
Schlemmer M, Spek A, Rodler S, Schott M, Casuscelli J, Staehler M
Cureus. 2019; 11(3):e4244.
PMID: 31131167
PMC: 6516620.
DOI: 10.7759/cureus.4244.
